Sponsors › Intarcia Therapeutics
Intarcia Therapeutics
Every GLP‑1 and incretin trial, approval and scheduled result we hold for Intarcia Therapeutics, drawn from ClinicalTrials.gov and Drugs@FDA.
Intarcia Therapeutics is a commercial sponsor with 10 trials in the incretin class on file here, across 2 molecules. The programme is split between 1 early-stage trial and 9 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market.
- Molecules
- exenatide · liraglutide
- Trials on file
- 10
- Active trials
- 0
- Results scheduled
- 0
- Approved FDA submissions
- 0
Trials on file
All 10 incretin trials recorded for this sponsor, active first.